Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.

Acevedo-Torres K, Berríos L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S.

DNA Repair (Amst). 2009 Jan 1;8(1):126-36. doi: 10.1016/j.dnarep.2008.09.004. Epub 2008 Nov 20.

2.

Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF.

Hum Mol Genet. 2010 Aug 15;19(16):3190-205. doi: 10.1093/hmg/ddq229. Epub 2010 Jun 7.

3.

Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.

Siddiqui A, Rivera-Sánchez S, Castro Mdel R, Acevedo-Torres K, Rane A, Torres-Ramos CA, Nicholls DG, Andersen JK, Ayala-Torres S.

Free Radic Biol Med. 2012 Oct 1;53(7):1478-88. doi: 10.1016/j.freeradbiomed.2012.06.008. Epub 2012 Jun 16.

4.

Selective striatal mtDNA depletion in end-stage Huntington's disease R6/2 mice.

Hering T, Birth N, Taanman JW, Orth M.

Exp Neurol. 2015 Apr;266:22-9. doi: 10.1016/j.expneurol.2015.02.004. Epub 2015 Feb 12.

PMID:
25682918
5.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

6.

Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.

Herbst EA, Holloway GP.

Neuroscience. 2015 Sep 10;303:515-23. doi: 10.1016/j.neuroscience.2015.07.025. Epub 2015 Jul 14.

PMID:
26186895
7.

hMTH1 expression protects mitochondria from Huntington's disease-like impairment.

Ventura I, Russo MT, De Nuccio C, De Luca G, Degan P, Bernardo A, Visentin S, Minghetti L, Bignami M.

Neurobiol Dis. 2013 Jan;49:148-58. doi: 10.1016/j.nbd.2012.09.002. Epub 2012 Sep 10.

9.

Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease.

Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF.

J Neurochem. 2001 Dec;79(6):1246-9.

10.

Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice.

Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H.

Acta Neuropathol. 2011 Apr;121(4):487-98. doi: 10.1007/s00401-010-0788-5. Epub 2010 Dec 16.

11.
12.

N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.

Wright DJ, Renoir T, Smith ZM, Frazier AE, Francis PS, Thorburn DR, McGee SL, Hannan AJ, Gray LJ.

Transl Psychiatry. 2015 Jan 6;5:e492. doi: 10.1038/tp.2014.131.

13.

Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.

Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ.

Eur J Neurosci. 2004 May;19(10):2799-807.

PMID:
15147313
14.

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.

Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH.

Hum Mol Genet. 2011 Apr 1;20(7):1438-55. doi: 10.1093/hmg/ddr024. Epub 2011 Jan 21.

15.

Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.

Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR.

J Neurosci. 2007 Oct 24;27(43):11758-68.

16.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

17.

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF.

J Comp Neurol. 2003 Oct 6;465(1):11-26.

PMID:
12926013
18.

Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop.

Kannike K, Sepp M, Zuccato C, Cattaneo E, Timmusk T.

J Biol Chem. 2014 Nov 21;289(47):32845-57. doi: 10.1074/jbc.M114.612424. Epub 2014 Sep 30.

19.

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH.

Ann Neurol. 2000 Jan;47(1):80-6.

PMID:
10632104
20.

Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Wang JQ, Chen Q, Wang X, Wang QC, Wang Y, Cheng HP, Guo C, Sun Q, Chen Q, Tang TS.

J Biol Chem. 2013 Feb 1;288(5):3070-84. doi: 10.1074/jbc.M112.407726. Epub 2012 Dec 17.

Items per page

Supplemental Content

Write to the Help Desk